TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06310720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Education
Description: 12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
Study: NCT03243058

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ILT-101 (Aldesleukin; IL-2)
Description: Administration of Low-Dose Interleukin-2 (ILT-101) for two years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ILT-101 (Aldesleukin; IL-2)
Description: Administration of Low-Dose Interleukin-2 (ILT-101) for two years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment-Placebo Arm
Description: Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Participants in this group will receive a placebo injection for two years.
Study: NCT05866185

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: The standard of care procedures for adults with clinically elevated anxiety and/or depression from their mental health provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy + Adhere.ly
Description: Participants receive therapy as usual enhanced with a simple, HIPAA-compliant, web-based application to help mental health providers implement homework during therapy for adults with elevated anxiety and/or depression. The three major components of the app help providers to (1) Practice interactive, digitized therapeutic exercises with patients in-session; (2) Remind patients to practice exercises for homework, and (3) Review homework during the next session.
Study: NCT06030700

Intervention type: OTHER
Intervention: Controlled Conditions
Description: Use of FoodImage app to take pictures of food and/or receipts.
Study: NCT05502081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab Drug Combination
Description: antiviral Monoclonal Antibodies
Study: NCT05238207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-001
Description: Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Original Fibre Metamucil
Description: Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
Study: NCT06478316

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intracervical block
Description: local injection of lidocain to the cervix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracervical block
Description: local injection of lidocain to the cervix
Study: NCT04158037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth App
Description: The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
Study: NCT06361394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness course
Description: The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course.
Study: NCT04189965

Intervention type: OTHER
Group type: OTHER
Intervention: Validation of virtual environment and auditive stimulation with virtual reality glasses (Pilot phase)
Description: The goal of this phase is the development of the experimental protocol in virtual reality. Virtual environment will be checked and auditive stimulation will be graduated.

Intervention type: OTHER
Group type: OTHER
Intervention: Electrical cutaneous stimulation and auditive stimulation (Principal Experimental phase)
Description: This phase is the principal step of the study: during moving in virtual environment, electrical stimulation on one hand and auditive stimulation will be applied. EEG, ECG and skin conductance will be measured during conditioning phase and extinction phase (day 1, 30 minutes each phase). Behavioral measures will be done throughout the 3 sessions (day 1, day 2 and day 30)

Intervention type: OTHER
Group type: OTHER
Intervention: Electrical cutaneous stimulation and auditive stimulation (Secondary Experimental phase)
Description: This phase is the same of the Principal Experimental phase except for the EEG that will not be performed.
Study: NCT06005818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab injection
Description: PD-1 antibody
Study: NCT05875857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid destruction education
Description: Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
Study: NCT06796725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: (1) The patient undergoes pseudo stimulus intervention in the first week and real stimulus intervention afterwards, which is blind to the patient. (2) Starting from the second week, true stimulation intervention will be conducted for 4 weeks, with each patient making an appointment for 1 month. On Day 7 after the patient intervention, Day 14, Day 30, Day 60, Day 90, Day 180 scales were used to evaluate follow-up.

Intervention type: DRUG
Group type: OTHER
Intervention: Sibelium
Description: Sibelium 10mg is taken orally every night for 4 weeks each course of treatment. Patients were evaluated and followed up with a scale based on medication intervention, including Day 7, Day 14, Day 30, Day 60, Day 90, and Day 180
Study: NCT06796322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive blood glucose meter
Description: Blood glucose were detected by non-invasive glucose meter at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.

Intervention type: DEVICE
Group type: OTHER
Intervention: fully automatic laboratory biochemical analyzer
Description: Blood glucose were detected by fully automatic laboratory biochemical analyzer using plasma sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.

Intervention type: DEVICE
Group type: OTHER
Intervention: fingertip capillary blood glucose meter
Description: Blood glucose were detected by fingertip capillary blood sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
Study: NCT06794567

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: Early access to genetic testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: Early access to genetic testing.
Study: NCT06793267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide (Maxolon)
Description: Participants will receive 0.15 mg/kg of metoclopramide administered intravenously. The drug will be diluted in 2 ml of solution prior to administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: patients will recive normal saline 0.9% 2ml intravenous
Study: NCT06797089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy plus scaling and root planing on left or right of mouth
Description: This device opens the upper airway by bringing the mandible forward to improve breathing during sleep. The mouth shield minimizes mouth breathing to optimize salivary function. Scaling and root planing (deep cleaning of all teeth requiring it).
Study: NCT06793189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab and Orelabrutinib
Description: Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days) and Orelabrutinib (150 mg once daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab, Orelabrutinib and Lenalidomide
Description: Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days), Orelabrutinib (150 mg once daily), and Lenalidomide (25 mg on days 2-11 of cycles 1-6, cycle length=21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).
Study: NCT06794229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Zanzalintinib 100mg orally (PO) once daily for 12 weeks up (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered at either 240mg IV every 2 weeks or 480mg IV 4 every weeks for 12 weeks (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1).
Study: NCT06797180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Education for Dementia Caregivers
Description: This group will receive 100 minutes of BPSD foundational education followed by 100 minutes of VR-based training focused on managing BPSD.
Study: NCT06794268

Intervention type: BIOLOGICAL
Intervention: Lisocabtagene maraleucel
Description: As per product label
Study: NCT06793072

Intervention type: DIAGNOSTIC_TEST
Intervention: Leptin concentration in blood serum
Description: Fasting plasma leptin concentration measurement with results expressed in pg/ml and comparison across all study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Leptin concentration in blood serum
Description: Fasting plasma leptin concentration measurement with results expressed in pg/ml and comparison across all study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Leptin concentration in blood serum
Description: Fasting plasma leptin concentration measurement with results expressed in pg/ml and comparison across all study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Resistin concentration in blood serum
Description: Fasting plasma resistin concentration measurement with results expressed in pg/ml and comparison across all study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Resistin concentration in blood serum
Description: Fasting plasma resistin concentration measurement with results expressed in pg/ml and comparison across all study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Resistin concentration in blood serum
Description: Fasting plasma resistin concentration measurement with results expressed in pg/ml and comparison across all study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Omentin-1 concentration in blood serum
Description: Fasting plasma omentin-1 concentration measurement with results expressed in pg/ml and comparison across all study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Omentin-1 concentration in blood serum
Description: Fasting plasma omentin-1 concentration measurement with results expressed in pg/ml and comparison across all study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Omentin-1 concentration in blood serum
Description: Fasting plasma omentin-1 concentration measurement with results expressed in pg/ml and comparison across all study arms
Study: NCT06797440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual tasks of digital technology
Description: The intervention activities of this study were cognitive and physical activity training using Nintendo Switch twice a week, 60 minutes each time (5 minutes of warm-up and cool-down exercises, 10 minutes of stretching exercises, and 40 minutes of exercise combined with cognitive training) for a total of 8 weeks. train. Both groups filled in basic data (demographics and disease characteristics) and underwent cognitive function measurements and physical activity function measurements at pretest (T0), 4th week (T1), and 8th week (T2).
Study: NCT06793540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SELF POSTUROTHERAPIE
Description: a simplified posturotherapy protocol that can be carried out by the patient himself. This protocol is based on the same principles as posturotherapy carried out by a physiotherapist by combining inclined positioning, percussion and diuresis.
Study: NCT05796921

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain
Description: Patients allocated to the probiotic arm will take the dietary supplement, containing 15 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days.
Study: NCT06795672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Three hours of cognitive rehabilitation per week, performed remotely and independently, using a computerized device, which is pre-programmed based on the patient's needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional in-person rehabilitation.
Description: Three hours of in-person cognitive rehabilitation per week using a computerized device.
Study: NCT06797167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injections of a filler gel containing cross-linked hyaluronic acid
Description: Vaginal Filler will be administered according to Investigator's judgment and Instruction For Use (IFU) to correct hypotrophy, improve the shape and increase the volume of the female external genital areas (labia majora). Vaginal Filler is a resorbable medical device available in packages containing 2 sterile pre-filled mono-use syringes of 1 ml with pre-assembled plunger rod and backstop, containing 25 mg/g cross-linked hyaluronic acid.~The injection is performed by medical personnel at visit V0 in one or both sides of the superficial subcutaneous layer of the labia majora, along its longitudinal axis.The dosage to be used for the individual case is at the doctor's discretion. An anesthetic may be applied (lidocaine 2% injection only in the cannula access point) to the affected area before the IP injection.~In order to maintain the results achieved, an eventual touch-up could be performed one months after the first treatment in the same areas of the first injection, at visit V2.
Study: NCT06792812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginger mouthwash
Description: contain Sulfetal Zn® (Zinc Coco Sulphate) has a cleansing and antibacterial action and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorohexidine mouthwash
Description: Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
Study: NCT06793735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation with Virtual Reality
Description: Participants assigned to the experimental group will engage in a six-week telerehabilitation program utilizing two non-immersive Virtual Reality (VR) applications, NeuroNation and The Sims Mobile. These apps are designed to enhance cognitive performance and social cognition skills through interactive and scientifically validated exercises. NeuroNation focuses on improving memory, attention, reasoning speed, and mental flexibility, while The Sims Mobile engages participants in realistic social scenarios that challenge their empathy, communication, and problem-solving abilities. The intervention involves three 30-minute sessions per week, which participants will complete remotely using smartphones or tablets. Therapists will provide weekly virtual check-ins to monitor progress, address questions, and ensure adherence to the protocol. This program aims to create an engaging and accessible rehabilitation experience while promoting real-life application of cognitive and social skills improv

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cognitive Rehabilitation
Description: Participants in the control group will follow a traditional rehabilitation protocol that relies on paper-based cognitive exercises. This program targets cognitive domains such as attention, memory, and executive functions through tasks like puzzles, memory challenges, and problem-solving activities. The intervention also spans six weeks, with participants completing three 30-minute sessions per week. During an initial session, participants will receive all necessary materials and instructions for completing the exercises independently at home. Therapists will provide weekly remote support via phone or video to track progress and address any concerns. This conventional approach serves as a baseline for comparison with the innovative telerehabilitation method in the experimental group.
Study: NCT06794112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animated Educational Video
Description: Both arms will receive standard care (written instructions), with the experimental arm receiving an additional animated video intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Instructions
Description: Standard written instructions for bowel preparation before colonoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Instructions
Description: Standard written instructions for bowel preparation before colonoscopy
Study: NCT06796946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deprescription of Antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram)
Description: Deprescription of Antidepressants Reduction or elimination of the dose of antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram) taken by patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deprescription of Antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram)
Description: Deprescription of Antidepressants Reduction or elimination of the dose of antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram) taken by patients
Study: NCT06795763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTO-PCI Procedure with Acolyte Catheter System
Description: Acolyte Catheter System is used to facilitate placement and positioning of guidewires and catheters within the coronary vasculature for the treatment of patients with coronary chronic total occlusions with persistent symptoms following medical therapy. The device provides real-time visualization of a coronary chronic total occlusion allowing for guidewire placement in the true lumen of the target vessel and subsequent revascularization.
Study: NCT06790758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma rich fibrin epidural injection by Racz catheter
Description: Patients will receive plasma-rich fibrin epidural injection by Racz catheter in post-dural puncture headache-guided optic nerve sheath diameter.
Study: NCT06795386

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Participants will include people with chronic widespread pain who will undergo bariatric surgery. All participants will receive this intervention and will not be randomized to this or other interventions.
Study: NCT06796335

Intervention type: OTHER
Intervention: RIGht
Description: The final intervention consists of five components; 1) education of nurses 2) a dialog tool used in a single session intervention and follow- up 3) a relative- to- relative list 4) video material 5) guidelines on how to document the relative involving plan in the patient's electronic journal.

Intervention type: OTHER
Intervention: RIGht
Description: The final intervention consists of five components; 1) education of nurses 2) a dialog tool used in a single session intervention and follow- up 3) a relative- to- relative list 4) video material 5) guidelines on how to document the relative involving plan in the patient's electronic journal.
Study: NCT06795139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial Enrollment Diversity Dashboard Behavioral
Description: A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.
Study: NCT06797739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: Patients will be asked to follow the Mediterranean Diet and to participate to an educational program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patients will be asked to follow Mediterranean Diet only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patients will be asked to follow Mediterranean Diet only
Study: NCT06793722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Technological device in circumcision
Description: Circumcision is performed by watching a video/playing a game during the procedure in children who are circumcised.